Upstream Bio
upstreambio.com
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma ...
Read more
Report
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
- Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track -
Read more
Report
Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week
Upstream Bio (UPB) saw its shares move slightly in recent trading, which has caught the attention of investors keen to track shifts in the biotech sector. The company's stock has gained 7% over the past week. See our latest analysis for Upstream Bio. Afte
Read more
Report
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug
Upstream Bio presents data suggesting verekitug offers greater potency than tezepelumab in targeting inflammatory diseases.
Read more
Report
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO
Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027.
Read more
Report
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB)
Upstream Bio is leveraging TSLP targeting for respiratory disorders treatment, with IPO funds and upcoming Chronic Rhinosinusitis data. Click for more on UPB.
Read more
Report
Upstream Bio stock rallies 32% following upsized $255M IPO (NASDAQ:UPB)
Upstream Bio (UPB) shares rallied 32% Friday following the asthma drug developer's $255M upsized initial public offering. Read more here.
Read more
Report
Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
- Treatment with verekitug led to rapid PD effects which were sustained for up to 24 weeks, supporting evaluation of dosing intervals of once every 12 or 24 weeks in ongoing Phase 2 clinical trials - - PK/PD modeling predicts substantially higher clinical
Read more
Report
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
- In a multiple-ascending dose (MAD) study in patients with asthma, up to 54% reduction in fractional exhaled nitric oxide concentration (FENO) was observed with administration of verekitug, with treatment effects sustained up to 24 weeks after last dose
Read more
Report
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
WALTHAM, Mass. - May 15, 2024 - Upstream Bio, Inc., a clinical-stage company focused on the development of verekitug, a potential first-in-class antagonist of the Thymic Stromal Lymphopoietin (TSLP) receptor that may deliver best-in-class efficacy for peo
Read more
Report
Show more news